论文部分内容阅读
目的探讨云克(99锝-亚甲基二磷酸盐)、甲氨蝶呤联合治疗类风湿关节炎(rheumatoid arthritis,RA)的疗效及其安全性。方法选取了53例活动期RA的临床资料进行回顾性分析,其中云克+甲氨蝶呤组22例,云克+甲氨蝶呤+来氟米特组31例,两组均接受相应药物治疗l2周。观察4、12周结束时临床症状改善、实验室指标变化及不良反应。结果 4、12周时两组的各项临床指标及实验室指标较治疗前均有显著性差异(P<0.05),但两组之间无显著差异(P>0.05)。不良事件两组均较少,两组之间总体比较差异无显著性意义(P>0.05)。结论云克(99锝-亚甲基二磷酸盐)和甲氨蝶呤联合治疗类风湿关节炎起效快,副作用少较小。
Objective To investigate the efficacy and safety of Yunke (99 technetium-methylene diphosphate) and methotrexate in the treatment of rheumatoid arthritis (RA). Methods The clinical data of 53 patients with active RA were retrospectively analyzed. Among them, 22 patients in Yunke + methotrexate group and 31 patients in Yunke + methotrexate + leflunomide group received the corresponding drugs Treatment l2 weeks. At the end of 4 and 12 weeks, clinical symptoms, laboratory changes and adverse reactions were observed. Results At 4 and 12 weeks, the clinical indexes and laboratory indexes in both groups were significantly different from those before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). Adverse events were less in both groups, with no significant difference between the two groups (P> 0.05). Conclusion Yunke (99 technetium-methylene diphosphate) combined with methotrexate treatment of rheumatoid arthritis onset faster, less side effects.